The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, D.C. Azar spoke about the need for “greater transparency surrounding how these [340B] discounts are being used” and “reforms to reduce the gap between discounted prices and the reimbursement provided.” In addition, Azar said change is coming for the larger issue of prescription drug pricing, “whether it’s painful or not for pharmaceutical companies.” He spoke about the administration’s request for information , which was released in May, on ways to lower drug prices and reduce out-of-pocket costs for consumers. “Something must be done about these skyrocketing list prices, and yet the system that has been built makes that nearly impossible,” he said. “Everyone in the system, from drug companies to pharmacy benefit managers to drug wholesalers makes their money as a share of list prices.”

Related News Articles

Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Insights and Analysis
As the 2019 chair of the AHA’s Section for Small or Rural Hospitals, I can attest that AHA is stepping up in a big way to grapple with the issues that affect…
Headline
Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing…
Headline
Committee Chairman Richard Neal, D-Mass., and Ranking Member Kevin Brady, R-Texas, said they are committed to working on bipartisan reforms to lower drug…
Headline
The AHA, Federation of American Hospitals, and American Society of Health-System Pharmacists today convened a panel of experts on Capitol Hill to discuss how…
Headline
Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples Act as it…